Esperion Therapeutics Inc (NASDAQ:ESPR) has earned a consensus recommendation of “Buy” from the fourteen analysts that are currently covering the company, MarketBeat reports. Eight analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $31.92.

Several equities research analysts recently issued reports on the company. Needham & Company LLC set a $25.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a research note on Saturday, March 18th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $30.00 price objective (up from $20.00) on shares of Esperion Therapeutics in a research note on Thursday, February 23rd. Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 2nd. Citigroup Inc. raised Esperion Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $14.00 to $39.00 in a research note on Tuesday, February 28th. Finally, J P Morgan Chase & Co reaffirmed a “hold” rating and set a $50.00 price target (up from $22.00) on shares of Esperion Therapeutics in a research note on Monday, March 20th.

In related news, Director Dov A. Md Goldstein sold 800,000 shares of the business’s stock in a transaction on Wednesday, March 22nd. The stock was sold at an average price of $41.66, for a total value of $33,328,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gilbert S. Omenn acquired 1,000 shares of the business’s stock in a transaction on Tuesday, March 21st. The stock was acquired at an average price of $42.26 per share, with a total value of $42,260.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $422,600. The disclosure for this purchase can be found here. 32.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of ESPR. Quantbot Technologies LP acquired a new position in shares of Esperion Therapeutics during the first quarter valued at about $158,000. C WorldWide Group Holding A S acquired a new position in shares of Esperion Therapeutics during the first quarter valued at about $162,000. Princeton Alpha Management LP acquired a new position in shares of Esperion Therapeutics during the first quarter valued at about $205,000. Bank of Montreal Can increased its position in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares during the last quarter. Finally, American International Group Inc. increased its position in shares of Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 584 shares during the last quarter. Hedge funds and other institutional investors own 81.45% of the company’s stock.

Shares of Esperion Therapeutics (NASDAQ ESPR) opened at 33.39 on Monday. Esperion Therapeutics has a one year low of $9.40 and a one year high of $48.21. The stock’s market cap is $754.28 million. The company has a 50 day moving average of $35.00 and a 200-day moving average of $26.03.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Monday, May 1st. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.36. During the same period in the previous year, the firm earned ($0.65) earnings per share. On average, analysts anticipate that Esperion Therapeutics will post ($6.69) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Brokerages Set Esperion Therapeutics Inc (ESPR) Price Target at $31.92” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/06/19/esperion-therapeutics-inc-espr-given-average-rating-of-buy-by-analysts-updated-updated.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Receive News & Stock Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related stocks with our FREE daily email newsletter.